Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
29.01
+2.16 (8.04%)
At close: Dec 20, 2024, 4:00 PM
29.03
+0.02 (0.07%)
After-hours: Dec 20, 2024, 5:35 PM EST
Beam Therapeutics Employees
Beam Therapeutics had 436 employees as of December 31, 2023. The number of employees decreased by 71 or -14.00% compared to the previous year.
Employees
436
Change (1Y)
-71
Growth (1Y)
-14.00%
Revenue / Employee
$801,933
Profits / Employee
-$329,337
Market Cap
2.31B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
CONMED | 4,000 |
Omnicell | 3,650 |
Premier | 2,900 |
Tandem Diabetes Care | 2,400 |
NeoGenomics | 2,100 |
GeneDx Holdings | 1,000 |
LeMaitre Vascular | 630 |
IDEAYA Biosciences | 124 |
BEAM News
- 13 days ago - Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 14 days ago - Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 15 days ago - Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer - GlobeNewsWire
- 17 days ago - Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader - GlobeNewsWire
- 5 weeks ago - Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch - Seeking Alpha
- 6 weeks ago - Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs - GlobeNewsWire